Supplier
Monongahela Valley Hospital, INC.
Monongahela Valley Hospital, INC. was paid $3.58M by Medicaid between Jan 2018 and Dec 2024, across 133 billing codes. Its largest line is 99284, emergency room visit (serious) — 36% of everything it billed.
33Billing provider infoMONONGAHELA VALLEY HOSPITAL, INC.
MONONGAHELA, PA 15063
MONONGAHELA, PA 15063
33aNPI1912905548assigned 07/08/2005
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$3.58M
24GClaims98,178
24DCodes billed133
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in Pennsylvania
Rank by total paid#32 of 279
Median peer was paid$181K
This provider vs. median20×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official STRISHOCK, JOURDAN controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 79 | $6K | |
| 2019 | 18 | $15.79 | |
| 2020 | 6,826 | $226K | |
| 2021 | 31,880 | $1.23M | |
| 2022 | 6,012 | $261K | |
| 2023 | 17,535 | $639K | |
| 2024incomplete | 35,828 | $1.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 36% | 7,279 | 7,082 | $1.28M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 4,899 | 4,764 | $551K |
| G0378 | Hospital observation service, per hour | 14% | 379 | 355 | $503K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.2% | 751 | 722 | $151K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.3% | 1,099 | 1,081 | $118K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 1,896 | 1,846 | $113K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 2.9% | 2,310 | 790 | $102K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 351 | 344 | $70K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 2,679 | 2,592 | $57K |
| 80053 | Comprehensive metabolic panel | 1.5% | 6,484 | 5,978 | $52K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 490 | 464 | $40K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,732 | 7,838 | $35K |
121 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 728 | $33K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,318 | $29K |
| 80050 | General health panel | <1% | 598 | $23K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 681 | $22K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,083 | $21K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 839 | $21K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 460 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 834 | $19K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 338 | $16K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 194 | $16K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 319 | $14K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 597 | $14K |
| 84484 | <1% | 1,991 | $13K | |
| 87625 | <1% | 276 | $11K | |
| 85730 | <1% | 2,314 | $11K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 128 | $11K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 502 | $11K |
| 83735 | <1% | 2,277 | $11K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,774 | $9K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 84 | $8K |
| 84703 | <1% | 1,102 | $8K | |
| 80061 | Lipid panel | <1% | 592 | $8K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 42 | $8K |
| 81001 | <1% | 3,807 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 440 | $7K |
| 85610 | <1% | 2,739 | $7K | |
| 87481 | <1% | 760 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,164 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,555 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 283 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 214 | $6K |
| 87480 | <1% | 207 | $5K | |
| 87660 | <1% | 208 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 146 | $5K |
| 81514 | <1% | 39 | $5K | |
| 83690 | <1% | 1,246 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 109 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 116 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 423 | $3K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 41 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 53 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 432 | $3K |
| 0002A | <1% | 55 | $3K | |
| J3490 | Unclassified drugs | <1% | 712 | $3K |
| 0001A | <1% | 54 | $3K | |
| 83605 | <1% | 412 | $2K | |
| A4657 | Syringe, with or without needle, each | <1% | 549 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 54 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 334 | $2K |
| 85378 | <1% | 309 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 122 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 50 | $2K |
| 84439 | <1% | 190 | $2K | |
| 93975 | <1% | 12 | $2K | |
| 87510 | <1% | 180 | $1K | |
| 82150 | <1% | 437 | $1K | |
| 87040 | <1% | 177 | $1K | |
| 80076 | <1% | 212 | $1K | |
| 93970 | <1% | 12 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 105 | $1K |
| 0004A | <1% | 24 | $1K | |
| 87070 | <1% | 197 | $966.08 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 25 | $935.88 |
| 84702 | <1% | 59 | $872.31 | |
| 82607 | <1% | 70 | $774.37 | |
| 81025 | <1% | 311 | $772.78 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 143 | $742.84 |
| 73630 | <1% | 90 | $713.09 | |
| 76536 | <1% | 12 | $680.12 | |
| 87077 | <1% | 140 | $625.65 | |
| 82550 | <1% | 150 | $606.68 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,273 | $541.53 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 297 | $539.29 |
| 86850 | <1% | 84 | $502.19 | |
| 73610 | <1% | 40 | $466.18 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 185 | $463.63 |
| 82077 | <1% | 39 | $460.60 | |
| 83540 | <1% | 61 | $420.27 | |
| 73564 | <1% | 32 | $412.16 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14 | $411.57 |
| 87186 | <1% | 76 | $407.39 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,758 | $386.11 |
| 80143 | <1% | 31 | $383.67 | |
| 80179 | <1% | 31 | $383.67 | |
| 82728 | <1% | 43 | $362.70 | |
| 73130 | <1% | 41 | $355.74 | |
| 84100 | <1% | 57 | $353.96 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,258 | $348.97 |
| 86803 | <1% | 16 | $345.61 | |
| 82570 | <1% | 41 | $310.16 | |
| 86901 | <1% | 99 | $292.22 | |
| 86900 | <1% | 100 | $288.81 | |
| 83880 | <1% | 28 | $285.71 | |
| 87275 | <1% | 27 | $263.88 | |
| 83550 | <1% | 56 | $227.92 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 38 | $219.30 |
| 73030 | <1% | 13 | $208.96 | |
| 86592 | <1% | 48 | $201.72 | |
| 87276 | <1% | 26 | $187.70 | |
| 87205 | <1% | 58 | $185.15 | |
| 86140 | <1% | 64 | $184.05 | |
| 85651 | <1% | 63 | $183.26 | |
| 82746 | <1% | 12 | $73.22 | |
| 87081 | <1% | 137 | $47.64 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 330 | $36.72 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 548 | $28.81 |
| J2704 | Injection, propofol, 10 mg | <1% | 250 | $28.39 |
| A9270 | Non-covered item or service | <1% | 1,427 | $17.03 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 72 | $9.71 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 296 | $5.94 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 112 | $3.53 |
| A4615 | Cannula, nasal | <1% | 16 | $0.88 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 43 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 76 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 49 | $0.00 |
| 90715 | 0% | 13 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 40 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 119 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 15 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 14 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTRISHOCK, JOURDAN (COMPLIANCE DIRECTOR)
Parent organizationPENN HIGHLANDS HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Highlands Hospital and Health Center | Connellsville, PA | $4.47M |
| Monongahela Valley Hospital, INC. | Monongahela, PA | $3.93M |
| Dubois Regional Medical Center | Clearfield, PA | $1.79M |
| Tyrone Hospital | Tyrone, PA | $1.44M |
| Penn Highlands Home Medical Equipment LLC | Clearfield, PA | $177K |
| Penn Highlands Home Medical Equipment LLC | Saint Marys, PA | $134K |
| Penn Highlands Home Medical Equipment LLC | Du Bois, PA | $29K |
| Highlands Hospital and Health Center | Connellsville, PA | $16K |
| Dubois Regional Medical Center | Du Bois, PA | $10K |
| J C Blair Memorial Hospital | State College, PA | $7K |
| Monongahela Valley Hospital, INC. | Monongahela, PA | $4K |
| JC Blair Memorial Hospital | Huntingdon, PA | $2K |
| Monongahela Valley Hospital, INC. | Monongahela, PA | $404.23 |
| J. C. Blair Memorial Hospital | Huntingdon, PA | $346.50 |
| Monongahela Valley Hospital, INC | Uniontown, PA | $320.93 |
| Mon-Vale Oncology, INC. | Monongahela, PA | $309.50 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.